EU approval for Palynziq in adult phenylketonuria
It’s the first substitution therapy approved in Europe to target the underlying cause of PKU by helping the body to break down Phe.
Read More
Tag: Palynziq
US clears first enzyme therapy for PKU
Biomarin’s Palynziq has been approved as the first enzyme therapy to treat the rare brain-threatening genetic disease phenylketonuria (PKU) in adults in the US.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
